Welcome Guest | Register / Login

Pharmaceuticals Industry Deals and Trends in March 2021 - Partnerships, Licensing, Investments, Mergers and Acquisitions (M&A)

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Pharmaceuticals & Healthcare, Global, Deal Summary
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, March 2021
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, March 2021
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, March 2021
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, March 2021
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type
3.1 Pharmaceuticals & Healthcare, Global, M&A, March 2021
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, March 2021
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, March 2021
3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, March 2021
3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, October 2020- March 2021
3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), March 2021
3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), October 2020- March 2021
3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, October 2020- March 2021
3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), October 2020- March 2021
3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2020- March 2021
4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2021
4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2021
4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), March 2021
4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), October 2020- March 2021
4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), October 2020- March 2021
4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), October 2020- March 2021
4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), October 2020- March 2021
5 & Healthcare, Global, Deal Summary by Therapy Area
5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, March 2021
5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, March 2021
5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, March 2021
5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, March 2021
5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, March 2021
5.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, March 2021
5.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Disorders, Deals, March 2021
6 Deal Summary by Geography
6.1 Pharmaceuticals & Healthcare, North America Deals, March 2021
6.2 Pharmaceuticals & Healthcare, Europe, Deals, March 2021
6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, March 2021
6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, March 2021
7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors
7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, October 2020- March 2021
7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, October 2020- March 2021
8 Further Information
8.1 Methodology
8.2 About GlobalData
8.3 Contact Us
8.4 Disclosure information
8.5 Disclaimer

List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, March 2021
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), March 2021
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, March 2021
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2020- March 2021
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, March 2021
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, March 2021
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, October 2020- March 2021
Table 13:Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), March 2021
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, October 2020- March 2021
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2020- March 2021
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), March 2021
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2020- March 2021
Table 21:Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2020- March 2021
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), October 2020- March 2021
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), October 2020- March 2021
Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), March 2021
Table 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, October 2020- March 2021
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), March 2021
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, March 2021
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, March 2021
Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, March 2021
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Table 37: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Table 38: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2020- March 2021

List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Figure 2: Pharmaceuticals & Healthcare, Global, Number of Deals (%), March 2021
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), March 2021
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2020- March 2021
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2020- March 2021
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number of Deals (%), March 2021
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), March 2021
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2020- March 2021
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2020- March 2021
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2020- March 2021
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2020- March 2021
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2020- March 2021
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2020- March 2021
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2020- March 2021
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number of Deals, October 2020- March 2021
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), October 2020- March 2021
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), March 2021
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Figure 32: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Figure 33: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2020- March 2021
Single User License: Report will be emailed in PDF format and can be accessed by a specific user. This License type allows the report to be Printed.
Site License: Report will be emailed in PDF and  allows only employees within the same geographical location within the organization to access it. This License type allows the report to be Printed.
Global Site License: Report will be emailed in PDF format and allows all employees within the organization to access it.  This License type allows the report to be Printed.
Why http://www.marketreportsonline.com/
Published By :GlobalData
Price
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy